Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia-Reference-Cited by-同舟云学术

Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia

Published:2016-12-30 Issue:13 Volume:23 Page:3297-3306
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Hu Yongxian,Wu Zhao,Luo Yi,Shi Jimin,Yu Jian,Pu Chengfei,Liang Zuyu,Wei Guoqing,Cui Qu,Sun Jie,Jiang Jing,Xie Jue,Tan Yamin,Ni Wanmao,Tu Jifang,Wang Jinping,Jin Aiyun,Zhang Hao,Cai Zhen,Xiao Lei,Huang He

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of early predictive biomarkers for severe cytokine release syndrome in pediatric patients with chimeric antigen receptor T-cell therapy;Frontiers in Immunology;2024-09-12

2. How can we improve the successful identification of patients suitable for CAR-T cell therapy?;Expert Review of Molecular Diagnostics;2024-09-11

3. CD19 CAR T cells for B cell malignancies: a systematic review and meta-analysis focused on clinical impacts of CAR structural domains, manufacturing conditions, cellular product, doses, patient’s age, and tumor types;BMC Cancer;2024-08-22

4. Comparing the Differences in Adverse Events among Chimeric Antigen Receptor T-Cell Therapies: A Real-World Pharmacovigilance Study;Pharmaceuticals;2024-08-05

5. CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory/relapsed B-cell acute lymphoblastic leukemia;Heliyon;2024-07